北京唯源立康

Beijing V-Canpharma Biotech is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative gene therapies using adeno-associated virus (AAV) vectors. The company focuses on treating rare genetic disorders, with a primary emphasis on hemophilia and metabolic diseases. Its lead candidate, VCN-001, is a gene therapy for Hemophilia B that has entered clinical trials in China. V-Canpharma leverages its proprietary AAV technology platform to design and manufacture high-efficiency gene delivery systems. The company aims to provide long-term, curative treatments for patients with unmet medical needs in the rare disease space. V-Canpharma is recognized as one of the early pioneers in the Chinese AAV gene therapy sector, led by experts with extensive experience in viral vector engineering.